BR112014008865A2 - imidazo[1,2-c]pirimidinas 5,7-substituídas - Google Patents

imidazo[1,2-c]pirimidinas 5,7-substituídas

Info

Publication number
BR112014008865A2
BR112014008865A2 BR112014008865A BR112014008865A BR112014008865A2 BR 112014008865 A2 BR112014008865 A2 BR 112014008865A2 BR 112014008865 A BR112014008865 A BR 112014008865A BR 112014008865 A BR112014008865 A BR 112014008865A BR 112014008865 A2 BR112014008865 A2 BR 112014008865A2
Authority
BR
Brazil
Prior art keywords
pyrimidines
substituted imidazo
malignancies
solvates
stereoisomers
Prior art date
Application number
BR112014008865A
Other languages
English (en)
Inventor
P Hache Bruno
Todd Eary C
F Kraser Christopher
Harvey Darren
a moreno David
Laird Ellen
James Hicken Erik
e robinson John
E Burgess Laurence
Ren Li
c munson Mark
Laurence Boys Mark
Groneberg Robert
T Schlachter Stephen
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of BR112014008865A2 publication Critical patent/BR112014008865A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

abstract compounds of formula i: i and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which r1, r2, r3, r4, r5, r6, x1 and x2 have the meanings given in the specification, are inhibitors of one or more jak kinases and are useful in the treatment of autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities. tradução do resumo resumo patente de invenção: "imidazo[1,2-c]pirimidinas 5,7-substituídas". compostos da fórmula i: i e estereoisômeros e sais farmaceuticamente aceitáveis e solvatos destes, em que r1, r2, r3, r4, r5, r6, x1 e x2 têm os significado dados no relatório descritivo, são inibidores de uma ou mais jak quinases e são úteis no tratamento de doenças autoimunes, doenças inflamatórias, rejeição de órgãos, tecidos e células transplantados, bem como distúrbios hematológicos e malignidades e suas comorbidades. 21021384v1
BR112014008865A 2011-10-12 2012-10-09 imidazo[1,2-c]pirimidinas 5,7-substituídas BR112014008865A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161546426P 2011-10-12 2011-10-12
PCT/US2012/059282 WO2013055645A1 (en) 2011-10-12 2012-10-09 5,7-substituted-imidazo[1,2-c]pyrimidines

Publications (1)

Publication Number Publication Date
BR112014008865A2 true BR112014008865A2 (pt) 2017-04-25

Family

ID=47071473

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014008865A BR112014008865A2 (pt) 2011-10-12 2012-10-09 imidazo[1,2-c]pirimidinas 5,7-substituídas

Country Status (19)

Country Link
US (1) US20140228349A1 (pt)
EP (1) EP2766368A1 (pt)
JP (1) JP2014528475A (pt)
KR (1) KR20140076619A (pt)
CN (1) CN103987713A (pt)
AR (1) AR088304A1 (pt)
AU (1) AU2012323399A1 (pt)
BR (1) BR112014008865A2 (pt)
CA (1) CA2851623A1 (pt)
CL (1) CL2014000931A1 (pt)
CO (1) CO6950483A2 (pt)
CR (1) CR20140216A (pt)
IL (1) IL231903A0 (pt)
MX (1) MX2014004473A (pt)
RU (1) RU2014118954A (pt)
SG (1) SG11201401342VA (pt)
TW (1) TW201326173A (pt)
UY (1) UY34388A (pt)
WO (1) WO2013055645A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130231340A1 (en) 2012-03-02 2013-09-05 Sareum Limited Pharmaceutical compounds
SG11201600977XA (en) 2013-08-21 2016-03-30 Alios Biopharma Inc Antiviral compounds
WO2015032423A1 (en) * 2013-09-03 2015-03-12 Sareum Limited Pharmaceutical compounds
TWI725004B (zh) * 2014-12-05 2021-04-21 美商亞雷生物製藥股份有限公司 4,6-經取代之吡唑并［1,5-ａ］吡
CA2979425C (en) 2015-01-20 2020-04-14 Wuxi Fortune Pharmaceutical Co., Ltd Jak inhibitor
MX370933B (es) 2015-04-29 2020-01-09 Wuxi Fortune Pharmaceuticals Co Ltd Inhibidores jak.
CN107531711B (zh) 2015-05-29 2020-03-31 无锡福祈制药有限公司 Janus激酶抑制剂
JP6505956B2 (ja) 2016-02-24 2019-04-24 ファイザー・インク ＪＡＫ阻害剤としてのピラゾロ［１，５−ａ］ピラジン−４−イル誘導体
GB201617871D0 (en) 2016-10-21 2016-12-07 Sareum Limited Pharmaceutical compounds
EP3668858A1 (en) 2017-08-14 2020-06-24 Pfizer Inc Pyrazolo[1,5-a]pyrazin-4-yl and related derivatives
EP3805219A4 (en) * 2018-06-06 2022-03-23 Gengle Therapeutics, Inc. PYRAZOLOPYRIMIDI DERIVATIVE, ITS USE AND PHARMACEUTICAL COMPOSITION
WO2020063751A1 (en) * 2018-09-27 2020-04-02 Fochon Pharmaceuticals, Ltd. Substituted imidazo [1, 2-a] pyridine and [1, 2, 4] triazolo [1, 5-a] pyridine compounds as ret kinase inhibitors
LT3873903T (lt) 2018-10-31 2024-05-10 Gilead Sciences, Inc. Pakeistieji 6-azabenzimidazolo junginiai, kaip hpk1 inhibitoriai
US11071730B2 (en) 2018-10-31 2021-07-27 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
CN111320624B (zh) * 2018-12-14 2023-05-12 中国医药研究开发中心有限公司 三唑并吡啶类和咪唑并吡啶类化合物及其制备方法和医药用途
CN113924301A (zh) * 2019-04-12 2022-01-11 北京普祺医药科技有限公司 一种吡唑并吡嗪衍生的化合物、药物组合物以及其用途
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
CN111039963B (zh) * 2019-12-31 2021-03-19 卓和药业集团有限公司 Wxfl10203614水溶性类似物及其合成方法
WO2021173476A1 (en) * 2020-02-24 2021-09-02 The Trustees Of Columbia University In The City Of New York Compounds, pharmaceutical formulations, and methods for treatment of cancer
EP3944859A1 (en) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
BR112023009116A2 (pt) * 2020-11-13 2023-10-03 Biogen Ma Inc Derivados de pirazolo[1,5-a]pirazina como inibidores de btk
TWI820622B (zh) 2021-03-04 2023-11-01 美商美國禮來大藥廠 Fgfr3抑制劑化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5682799A (en) 1998-08-21 2000-03-14 Parker Hughes Institute Quinazoline derivatives
JP2001302667A (ja) * 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
CN103214483B (zh) * 2005-12-13 2014-12-17 因塞特公司 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2，3-b]吡啶和吡咯并[2，3-b]嘧啶
AU2007323725B2 (en) * 2006-11-22 2014-02-20 Incyte Holdings Corporation Imidazotriazines and imidazopyrimidines as kinase inhibitors
DE102007012645A1 (de) * 2007-03-16 2008-09-18 Bayer Healthcare Ag Substituierte Imidazo- und Triazolopyrimidine
CL2008001709A1 (es) * 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
SG184870A1 (en) * 2010-04-14 2012-11-29 Array Biopharma Inc 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases

Also Published As

Publication number Publication date
SG11201401342VA (en) 2014-09-26
TW201326173A (zh) 2013-07-01
JP2014528475A (ja) 2014-10-27
AR088304A1 (es) 2014-05-21
CR20140216A (es) 2014-08-21
AU2012323399A1 (en) 2014-05-29
RU2014118954A (ru) 2015-11-20
IL231903A0 (en) 2014-05-28
US20140228349A1 (en) 2014-08-14
UY34388A (es) 2014-04-30
MX2014004473A (es) 2015-04-14
EP2766368A1 (en) 2014-08-20
CN103987713A (zh) 2014-08-13
CA2851623A1 (en) 2013-04-18
CO6950483A2 (es) 2014-05-20
WO2013055645A1 (en) 2013-04-18
KR20140076619A (ko) 2014-06-20
CL2014000931A1 (es) 2014-08-29

Similar Documents

Publication Publication Date Title
BR112014008865A2 (pt) imidazo[1,2-c]pirimidinas 5,7-substituídas
CO6630187A2 (es) 5.7-sustituido -imidazol[1.2-c]pirimidinas como inhibidores de cinasas jak
BR112017011798A2 (pt) 4,6-substituído-pirazolo[1,5-a] pirazinas como inibidores janus cinase
CL2016001055A1 (es) Compuestos derivados de fenil-aminopirimidina, inhibidores de la tirosina quinasa de bruton (btk), composicion farmaceutica; combinacion farmaceutica; útiles en el tratamiento de enfermedades autoinmunes, inflamatorias, alergicas, de las vias aereas, entre otras.
EA201490859A1 (ru) Алкилированные соединения пиперазина в качестве ингибиторов тирозинкиназы брутона
UY33648A (es) Derivados de bencimidazol como inhibidores de cinasa pi3
TR201909849T4 (tr) Btk etkinliği inhibitörleri olarak heteroaril piridon ve aza-piridon bileşikleri.
MX2014005285A (es) Compuestos biciclicos de piperazina.
EA202090291A3 (ru) Производные бипиразола в качестве ингибиторов jak
BR112012020693A2 (pt) derivados de ciclobutano e metilciclobutano como inibidores de janus quinase
BR112014018524A8 (pt) Derivados de pirimido [4,5-b]indol, seus usos, composição farmaceutica, e método in vivo ou ex vivo para aumentar as células estaminais e/ou progenitoras
CO6440524A2 (es) Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la quinasa janus.
EA201000297A1 (ru) Конденсированные бициклические имидазолы
MX347917B (es) Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso.
BR112013020329A2 (pt) compostos heterocíclicos como inibidores da pi3-quinase
MX2014005282A (es) Compuestos de 8-fluoroftalazin-1 (2h) -ona.
WO2011080568A8 (en) Novel pyrimidine compounds as mtor and pi3k inhibitors
MX2013004298A (es) Derivados de quinazolin-4 (3h)-ona utilizados como inhibidores de pi3 cinasa.
EA201890827A1 (ru) Конденсированные производные пиразола в качестве ингибиторов киназы
IN2015DN03751A (pt)
EA201101186A1 (ru) Конденсированные пиримидины
IN2014CN03597A (pt)
MX2012006822A (es) 1,7-diazacarbazoles y metodos de uso.
EA201290744A1 (ru) Имидазо[1,2-b][1,2,4]триазины в качестве c-met ингибиторов
NZ703343A (en) Phenyl amino pyrimidine bicyclic compounds and uses thereof

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]